AMRA Launches Scientific Advisory Board for Metabolic Disease
News
5 October 2017

AMRA Launches Scientific Advisory Board for Metabolic Disease

Linköping, Sweden October 5, 2017. AMRA is proud to announce the expansion of its Scientific Advisory Board to include four new members: Ian Neeland, Claude Sirlin, Miriam Vos, and Manu Chakravarthy. Each new advisor contributes years of expertise and significant networks across the metabolic, obesity, diabetes, cardiovascular and liver arenas, all of which will support AMRA’s continued development of metabolic applications. Longstanding advisors Jimmy Bell and Sven Enerbäck will continue to work with AMRA and the expanded metabolic team, while Mark Adkins will continue to support AMRA’s growing applications in the musculoskeletal field.

Ian Neeland is a general cardiologist with special expertise in obesity and cardiovascular disease, as well as noninvasive imaging at the UT Southwestern Medical Center in Dallas, US. He is active in both research and patient care. His research focuses on cardiovascular disease, diabetes, and obesity.
  
Claude B. Sirlin is Professor and Vice Chair (Translational Research) of Radiology at the University of California, San Diego. His research focuses on MRI and quantitative ultrasound of liver cancer and chronic liver disease. He founded and directs UC San Diego Health’s Liver Imaging Group, which actively collaborates with hepatologists, surgeons, pathologists and statisticians to advance screening, diagnosis, treatment and outcomes of individuals with liver disease.

Miriam Vos is Associate Professor of Pediatrics at Emory University School of Medicine, and Director of Transplant Wellness at Children’s Healthcare of Atlanta. She specializes in the treatment of gastrointestinal disease in children, as well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity Solution for Kids.

Manu Chakravarthy is the CMO and Senior Vice President, Clinical Development for Axcella Health. Previously, Manu served as the Global Head of External R&D in diabetes and cardiovascular research at Eli Lilly & Co, and as industry co-leader of the Innovative Medicine Initiative’s LITMUS project, one of the largest public-private consortia to elucidate noninvasive biomarkers for NAFLD.

Jimmy Bell is a Professor of Human Metabolism at the University of Westminster and the Director of the Research Centre for Optimal Health (ReCOH), which he created to focus on research in obesity and the factors that determine optimal health and accelerated ageing. Jimmy is currently holding an assignment as PI for the UK Biobank (Enhanced Phenotyping).

Sven Enerbäck was appointed as full professor of Medical Genetics at the Medical Faculty of University of Gothenburg in 2000. His research focuses upon metabolism, particularly on white and brown adipose tissue and its role in systemic energy turn-over. He is an elected Member of The Royal Society of Arts and Sciences and the Medical Class of The Swedish Royal Academy of Science.

Mark Adkins is a Consultant within the Department of Radiology and Division of Musculoskeletal Radiology at Mayo Clinic, and an Assistant Professor of Radiology within the Mayo Clinic College of Medicine. He has been Director of the Musculoskeletal Imaging Fellowship Program at the Mayo School of Graduate Medical Education since 1997, and was Chair of the Division of Musculoskeletal Radiology at Mayo Clinic for 7 years.

Tommy Johansson, CEO of AMRA, said “We are so pleased that these advisors have joined to support the advancement of our research and clinical applications across the metabolic diseases, and that we also have the opportunity to expand our initiatives in the musculoskeletal space. Each of these individuals has shown a great support for the work we are doing and will be an instrumental part of our continued growth and success.”

For more information, please visit our website: www.amra.se.

Relevant Information